Form 4: PLUS THERAPEUTICS Director Granted Stock Options

PLUS THERAPEUTICS, INC. Director Howard Clowes was granted 297,794 stock options with an exercise price of $0.5744 per share.

Summary

• Howard Clowes, a Director of PLUS THERAPEUTICS, INC. (PSTV), was granted 297,794 stock options.
• The transaction date for the grant was August 13, 2025.
• Each stock option has an exercise price of $0.5744.
• The options vest monthly over 12 months from the grant date, or in full on the Issuer's 2026 Annual Stockholder Meeting, subject to continued service.
• The options have an expiration date of August 12, 2035.
• Following this transaction, Howard Clowes beneficially owns 297,794 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for aligning management incentives with shareholder interests, indicating continued commitment from key personnel. It's a routine compensation event that generally supports corporate governance and long-term value creation.

Positives

• The grant of stock options to a director aligns management's financial interests with those of shareholders, potentially incentivizing long-term value creation.
• This type of compensation can aid in the retention of key personnel, ensuring continuity in leadership.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholder equity, although this is a common aspect of equity compensation plans.

Future Outlook

The granted stock options are scheduled to vest monthly over a 12-month period from the grant date, or fully vest on the Issuer's 2026 Annual Stockholder Meeting, contingent on the reporting person's continued service.

Industry Context

This filing represents a routine compensation event for a director within the biotechnology or pharmaceutical industry, where equity grants are a common component of executive and board remuneration to align interests with long-term company performance.

Related Party Transactions

• Grant of 297,794 stock options to Howard Clowes, a Director of PLUS THERAPEUTICS, INC., as part of his compensation.

Stakeholder Impact

• Shareholders: Potential for enhanced alignment of the director's interests with shareholder value; potential future dilution if options are exercised.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Options will vest monthly over 12 months from the grant date (August 13, 2025).
• Options may vest in full on the Issuer's 2026 Annual Stockholder Meeting, if earlier than the monthly vesting schedule.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to a director, which is a standard compensation practice aimed at aligning management incentives with shareholder interests. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell the stock.

Keywords

PLUS THERAPEUTICS, PSTV, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Howard Clowes